PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ

Cytokine

Volumn 55, Issue 2, 2011, Pages 202-210

  Hirsch, Jennifer ^a   Johnson, Christina Lisa ^a   Nelius, Thomas ^a   Kennedy, Ronald ^a   Riese, Werner de ^a   Filleur, Stéphanie ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

IL8; NF B; PEDF; PEDFR; Prostate cancer

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHOLIPASE A2; PIGMENT EPITHELIUM DERIVED FACTOR; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; MALE; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; EYE PROTEINS; HUMANS; INTERLEUKIN-8; MALE; NERVE GROWTH FACTORS; NF-KAPPA B; PHOSPHOLIPASES A2; PPAR GAMMA; PROSTATIC NEOPLASMS; RECEPTORS, NEUROPEPTIDE; SERPINS;

EID: 79959573863     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.04.010     Document Type: Article

References (79)

1. Filleur S., Nelius T., de Riese W., Kennedy R.C. Characterization of PEDF: a multi-functional serpin family protein. J Cell Biochem 2009, 106:769-775.
2. Fernandez-Garcia N.I., Volpert O.V., Jimenez B. Pigment epithelium-derived factor as a multifunctional antitumor factor. J Mol Med 2007, 85:15-22.
3. Ek E.T., Dass C.R., Choong P.F. PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med 2006, 12:497-502.
4. Ek E.T., Dass C.R., Choong P.F. Pigment epithelium-derived factor: a multimodal tumor inhibitor. Mol Cancer Ther 2006, 5:1641-1646.
5. Takanohashi A., Yabe T., Schwartz J.P. Pigment epithelium-derived factor induces the production of chemokines by rat microglia. Glia 2005, 51:266-278.
6. Wang J.J., Zhang S.X., Mott R., Chen Y., Knapp R.R., Cao W., et al. Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am J Physiol Renal Physiol 2008, 294:F1166-F1173.
7. Zamiri P., Masli S., Streilein J.W., Taylor A.W. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci 2006, 47:3912-3918.
8. Zhang S.X., Wang J.J., Gao G., Shao C., Mott R., Ma J.X. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. Faseb J 2006, 20:323-325.
9. Doll J.A., Stellmach V.M., Bouck N.P., Bergh A.R., Lee C., Abramson L.P., et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003, 9:774-780.
10. Halin S., Wikstrom P., Rudolfsson S.H., Stattin P., Doll J.A., Crawford S.E., et al. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res 2004, 64:5664-5671.
11. Uehara H., Miyamoto M., Kato K., Ebihara Y., Kaneko H., Hashimoto H., et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004, 64:3533-3537.
12. Crawford S.E., Stellmach V., Ranalli M., Huang X., Huang L., Volpert O., et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 2001, 114:4421-4428.
13. Garcia M., Fernandez-Garcia N.I., Rivas V., Carretero M., Escamez M.J., Gonzalez-Martin A., et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 2004, 64:5632-5642.
14. Guan M., Yam H.F., Su B., Chan K.P., Pang C.P., Liu W.W., et al. Loss of pigment epithelium derived factor expression in glioma progression. J Clin Pathol 2003, 56:277-282.
15. Filleur S., Volz K., Nelius T., Mirochnik Y., Huang H., Zaichuk T.A., et al. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 2005, 65:5144-5152.
16. Volpert O.V., Zaichuk T., Zhou W., Reiher F., Ferguson T.A., Stuart P.M., et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002, 8:349-357.
17. Abe R., Shimizu T., Yamagishi S., Shibaki A., Amano S., Inagaki Y., et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 2004, 164:1225-1232.
18. Mirochnik Y., Aurora A., Schulze-Hoepfner F.T., Deabes A., Shifrin V., Beckmann R., et al. Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth. Clin Cancer Res 2009, 15:1655-1663.
19. Guan M., Pang C.P., Yam H.F., Cheung K.F., Liu W.W., Lu Y. Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther 2004, 11:325-332.
20. Takenaka K., Yamagishi S., Jinnouchi Y., Nakamura K., Matsui T., Imaizumi T. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci 2005, 77:3231-3241.
21. Zhang T., Guan M., Xu C., Chen Y., Lu Y. Pigment epithelium-derived factor inhibits glioma cell growth in vitro and in vivo. Life Sci 2007, 81:1256-1263.
22. Bilak M.M., Corse A.M., Bilak S.R., Lehar M., Tombran-Tink J., Kuncl R.W. Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J Neuropathol Exp Neurol 1999, 58:719-728.
23. Alberdi E., Aymerich M.S., Becerra S.P. Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons. Evidence for a PEDF receptor. J Biol Chem 1999, 274:31605-31612.
24. Aymerich M.S., Alberdi E.M., Martinez A., Becerra S.P. Evidence for pigment epithelium-derived factor receptors in the neural retina. Invest Ophthalmol Vis Sci 2001, 42:3287-3293.
25. Becerra S.P., Perez-Mediavilla L.A., Weldon J.E., Locatelli-Hoops S., de S.S.P., Notari L., et al. pigment epithelium-derived factor (PEDF) binds to hyaluronan:Mapping of a hyaluronan binding site. J Biol Chem 2008, 281:38022-38037.
26. Notari L, Baladron V, Aroca-Aguilar JD, Balko N, Heredia R, Meyer C, et al. Identification of a lipase-linked cell-membrane receptor for pigment epithelium-derived factor (PEDF). J Biol Chem 2006.
27. Chung C., Doll J.A., Gattu A.K., Shugrue C., Cornwell M., Fitchev P., et al. Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). J Hepatol 2008, 48:471-478.
28. Vandercappellen J., Van Damme J., Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008, 267:226-244.
29. Kobayashi Y. Neutrophil infiltration and chemokines. Crit Rev Immunol 2006, 26:307-316.
30. Bizzarri C., Beccari A.R., Bertini R., Cavicchia M.R., Giorgini S., Allegretti M. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 2006, 112:139-149.
31. Lu Y., Cai Z., Xiao G., Keller E.T., Mizokami A., Yao Z., et al. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 2007, 67:3646-3653.
32. Begley L.A., Kasina S., Mehra R., Adsule S., Admon A.J., Lonigro R.J., et al. CXCL5 promotes prostate cancer progression. Neoplasia 2008, 10:244-254.
33. Moore B.B., Arenberg D.A., Stoy K., Morgan T., Addison C.L., Morris S.B., et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 1999, 154:1503-1512.
34. Araki S., Omori Y., Lyn D., Singh R.K., Meinbach D.M., Sandman Y., et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007, 67:6854-6862.
35. Seaton A., Scullin P., Maxwell P.J., Wilson C., Pettigrew J., Gallagher R., et al. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 2008, 29:1148-1156.
36. Huang J., Yao J.L., Zhang L., Bourne P.A., Quinn A.M., di Sant'Agnese P.A., et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 2005, 166:1807-1815.
37. Murphy C., McGurk M., Pettigrew J., Santinelli A., Mazzucchelli R., Johnston P.G., et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 2005, 11:4117-4127.
38. Shen H., Lentsch A.B. Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Am J Physiol Cell Physiol 2004, 286:C840-C847.
39. Engl T., Relja B., Blumenberg C., Muller I., Ringel E.M., Beecken W.D., et al. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 2006, 78:1784-1793.
40. Reiland J., Furcht L.T., McCarthy J.B. CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate 1999, 41:78-88.
41. Keshamouni V.G., Arenberg D.A., Reddy R.C., Newstead M.J., Anthwal S., Standiford T.J. PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia 2005, 7:294-301.
42. Ho T.C., Chen S.L., Yang Y.C., Liao C.L., Cheng H.C., Tsao Y.P. PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells. Cardiovasc Res l 2007, 76:213-223.
43. Ho T.C., Yang Y.C., Chen S.L., Kuo P.C., Sytwu H.K., Cheng H.C., et al. Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma. Mol Immunol 2008, 45:898-909.
44. Gurnell M., Wentworth J.M., Agostini M., Adams M., Collingwood T.N., Provenzano C., et al. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J Biol Chem 2000, 275:5754-5759.
45. Greco W.R., Faessel H., Levasseur L. The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers?. J Natl Cancer Inst 1996, 88:699-700.
46. Notari L., Miller A., Martinez A., Amaral J., Ju M., Robinson G., et al. Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia. Invest Ophthalmol Vis Sci 2005, 46:2736-2747.
47. Smith N.D., Schulze-Hoepfner F.T., Veliceasa D., Filleur S., Shareef S., Huang L., et al. Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism. J Urol 2008, 179:2427-2434.
48. Burton J.D., Goldenberg D.M., Blumenthal R.D. Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res 2008, 2008:494161.
49. Veliceasa D., Schulze-Hoepfner F.T., Volpert O.V. PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments. PPAR Res 2008, 2008:945275.
50. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995, 270:12953-12956.
51. Pascual G., Glass C.K. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab 2006, 17:321-327.
52. Ricote M., Glass C.K. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 2007, 1771:926-935.
53. Cummings B.S. Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol 2007, 74:949-959.
54. Balsinde J. Roles of various phospholipases A2 in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling. Biochem J 2002, 364:695-702.
55. Goetzl E.J., Tigyi G. Lysophospholipids and their G protein-coupled receptors in biology and diseases. J Cell Biochem 2004, 92:867-868.
56. Scott K.F., Sajinovic M., Hein J., Nixdorf S., Galettis P., Liauw W., et al. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie 2010, 92:601-610.
57. Hui K., Li H.Z., Gang Wei, Qingchun Cai, Libo Yan, Yan Xu Tumor Cell Group VIA Phospholipase A2 Is Involved in Prostate Cancer Development. The Prostate 2011, 71:373-384.
58. Li H., Zhao Z., Wei G., Yan L., Wang D., Zhang H., et al. Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development. Faseb J 2010, 24:4103-4116.
59. Nicotera T.M., Schuster D.P., Bourhim M., Chadha K., Klaich G., Corral D.A. Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells. Prostate 2009, 69:1270-1280.
60. Sun B., Zhang X., Yonz C., Cummings B.S. Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells. Biochem Pharmacol 2010, 79:1727-1735.
61. Li H., Zhang H., Wei G., Cai Q., Yan L., Xu Y. Tumor cell group via phospholipase A(2) is involved in prostate cancer development. Prostate 2011, 71:373-384.
62. Oka T., Murata Y., Namba M., Yoshimizu T., Toyomura T., Yamamoto A., et al. A4, a unique kidney-specific isoform of mouse vacuolar H+-ATPase subunit a. J Biol Chem 2001, 276:40050-40054.
63. Matsuo Y., Raimondo M., Woodward T.A., Wallace M.B., Gill K.R., Tong Z., et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 2009, 125:1027-1037.
64. Rubie C., Kollmar O., Frick V.O., Wagner M., Brittner B., Graber S., et al. Differential CXC receptor expression in colorectal carcinomas. Scand J Immunol 2008, 68:635-644.
65. Varney M.L., Johansson S.L., Singh R.K. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 2006, 125:209-216.
66. Kim S.J., Uehara H., Karashima T., McCarty M., Shih N., Fidler I.J. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 2001, 3:33-42.
67. Singh S., Sadanandam A., Nannuru K.C., Varney M.L., Mayer-Ezell R., Bond R., et al. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res 2009, 15:2380-2386.
68. Wente M.N., Keane M.P., Burdick M.D., Friess H., Buchler M.W., Ceyhan G.O., et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 2006, 241:221-227.
69. Shen H., Schuster R., Lu B., Waltz S.E., Lentsch A.B. Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 2006, 66:1721-1728.
70. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993, 71:1098-1109.
71. Oudard S., Banu E., Beuzeboc P., Voog E., Dourthe L.M., Hardy-Bessard A.C., et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005, 23:3343-3351.
72. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
73. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
74. Nelius T., Klatte T., Yap R., Kalinski T., Ropke A., Filleur S., et al. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. BJU Int 2006, 98:580-585.
75. Nelius T., Reiher F., Lindenmeir T., Klatte T., Rau O., Burandt J., et al. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. Onkologie 2005, 28:573-578.
76. Wilson C., Purcell C., Seaton A., Oladipo O., Maxwell P.J., O'Sullivan J.M., et al. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther 2008, 327:746-759.
77. Wilson C., Wilson T., Johnston P.G., Longley D.B., Waugh D.J. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 2008, 7:2649-2661.
78. Wilson C., Scullin P., Worthington J., Seaton A., Maxwell P., O'Rourke D., et al. Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. Br J Cancer 2008, 99:2054-2064.
79. Mijatovic T., Mahieu T., Bruyere C., De Neve N., Dewelle J., Simon G., et al. UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia 2008, 10:573-586.